Who We Are
AIM-HI was born out of National Foundation for Cancer Research (NFCR) to solve unmet needs in cancer research and drug development. AIM-HI’s mission is to provide critically needed seed funding and networks to oncology startups and help translate breakthroughs in discoveries into effective new cancer therapies and diagnosis.
Three Co-Founders of the AIM-HI Accelerator Fund: Director Franklin Salisbury, Jr., President & CEO Sujuan Ba, Ph.D., Chairman Charlie Weatherspoon (left to right)
NFCR is a charity for cancer research co-founded by Nobel Laureate Dr. Albert Szent-Györgyi in 1973. In its 49-year history, NFCR has funded more than $390 million cancer research and public prevention education. NFCR has long been a catalyst for the kinds of “disruptive technologies” that are both accelerating innovation and bringing hope and promise to patients suffering with cancer.
Too many scientific breakthroughs still remain at the bench and are not being translated into next-generation cancer therapies, diagnostics and prevention strategies. Unless and until we can bring these breakthroughs through clinic trials to gain FDA approval, next-generation cancer therapies, diagnostics and prevention strategies will remain at the bench.
In 2019 we launched the AIM-HI Accelerator Fund to provide funding to speed the development of effective new cancer therapies. The AIM-HI Accelerator Fund is a new approach to cancer research and harnesses the power of donors, entrepreneurial scientists, and business leaders by making the impact investments which will turbo charge the translation of promising discoveries from bench to bedside.
The AIM-HI Accelerator Fund bridges the gap between basic research breakthroughs and the clinical drug development required for FDA approval—making possible new cancer treatments and give cancer patients hope and promise for a cure.